PTIX - Protagenic Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Protagenic Therapeutics, Inc.

149 Fifth Avenue
Suite 500
New York, NY 10010
United States

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Garo H. ArmenCo-Founder & Exec. ChairmanN/AN/A1953
Dr. Alexander K. Arrow C.F.A., M.D., CFACFO, Compliance Officer & Sec.125kN/A1971
Dr. Dalia BarsyteChief Technology AdvisorN/AN/AN/A
Dr. David A. LovejoyChief Scientific OfficerN/AN/AN/A
Dr. Robert B. SteinChief Scientific Advisor & DirectorN/AN/A1951
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Protagenic Therapeutics, Inc. engages in the discovery and development of therapeutics to treat central nervous system disorders. Its lead drug candidate is PT00114, which is in clinical proof-of-concept studies for the treatment-resistant depression and/or post-traumatic stress disorder. The company is based in New York, New York.

Corporate Governance

Protagenic Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.